The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate whether statin therapy utilizing the drug Lipitor (atorvastatin) might be effective in preventing short-and long-term atrial fibrillation (AF) following a left atrial ablation procedure. We further hypothesize this reduction will result from diminished peri-procedural inflammation, which will be reflected in lower C-Reactive Protein (CRP) values in the blood.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Patients > or = to 18 years of age

• Clinically indicated left atrial ablation procedure for atrial fibrillation

Exclusion Criteria:

• Known malignancy

• Known inflammatory disease

• Surgery or trauma or myocardial infarction in the previous month

• Known contraindication to statin therapy

• Elevated liver enzymes above two times the upper limit of normal

• Patients already receiving therapy with any statin, niacin or fibrates at the time of their randomization